Men with larger waists more likely to die of prostate cancer

September 01, 2020

A study of more than 200,000 UK men, being presented at this year's European and International Conference on Obesity (ECOICO), held online this year from September 1-4, reveals that there is a link between central adiposity (concentration of body fat around the belly and waist) and the risk of death from prostate cancer.

Prostate cancer is the second most common cause of cancer-specific death among men in the UK. The disease affects one in six men during their lifetime, causing more than a quarter of all new male cancer cases, and almost 12,000 deaths every year in the UK. There is some evidence that suggests a relationship between adiposity (amount of body fat) and likelihood of dying from prostate cancer, but more research was needed to confirm this association and determine whether it is not just the amount, but also the distribution of fat within the body that has an impact on risk.

The study, conducted by Dr Aurora Perez-Cornago and colleagues at the Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK and funded by Cancer Research UK, aimed to understand how both total adiposity and the distribution of fat in the body relate to fatal prostate cancer.

The team selected 218,225 men who were voluntary participants in the UK Biobank study (500,000 volunteers age 40-69 years recruited between 2006 and 2010) who were free from cancer at the baseline date. Their health was followed for 10.8 years using data from health administrative databases, and details of body mass index (BMI), total body fat percentage (measured using bioimpedance), waist circumference, and waist-to-hip ratio were collected when each volunteer was recruited. Complex statistical analyses that accounted for medical history, and socioeconomic and lifestyle factors were used to estimate links between the risk of dying from prostate cancer and these measures of adiposity.

During the follow-up period 571 men died from prostate cancer. The researchers discovered that while there was no clear association of BMI or total fat percentage with risk, there was a positive link between measures of central adiposity and risk of prostate cancer death. Those in the top 25% for waist circumference were 35% more likely to die of prostate cancer than men in the bottom 25%, while those in the top 25% for waist-to-hip ratio were 34% more likely to die than men in the bottom 25%.

Dr Perez-Cornago concludes: "We found a significant association between concentration of body fat around the belly and waist and the risk of prostate cancer death, but no clear association between total body fat and risk of prostate cancer death. However, a larger number of cases in this study together with studies in other populations are needed to confirm these findings."

She adds: "A high BMI increases the risk of other diseases, including other types of cancer, so people should consider the implications of excess body fat wherever it is found in the body."

"Future work will examine associations between adiposity and aggressive types of prostate cancer, including advanced stage and high-grade disease."

European Association for the Study of Obesity

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to